左归丸合下瘀血汤治疗原发性骨质疏松症(肾虚血瘀型)临床疗效观察

Clinical effect observation of Zuoguiwan and Xiayuxue decoction in the treatment of primary osteoporosis(Kidney deficiency and blood stasis type

目的:评价采用左归丸合下瘀血汤加减,补肾活血治疗对原发性骨质疏松人群的临床疗效意义。方法:收集2013年8月—2015年8月本院确诊为原发性骨质疏松症病例,筛选其中属肾虚血瘀型原发性骨质疏松症患者作为研究对象,在患者知情同意的情况下,予左归丸合下瘀血汤加减,补肾活血治疗,观察分析疗效,并与同期其他常规治疗的肾虚血瘀型原发性骨质疏松症病例进行对比,评估疗效。结果:治疗组患者治疗总有效率显著高于对照组的总有效率,差异具有统计学意义(P<0.05)。两组患者治疗前BMD值无明显差异(P>0.05),治疗后3个月及治疗后6个月,治疗组的BMD值显著高于对照组的总有效率,差异具有统计学意义(P<0.05)。结论:采用左归丸合下瘀血汤加减,补肾活血治疗对原发性骨质疏松,能够有效治疗原发性骨质疏松,并且能够有效增加骨密度,值得在临床上进行推广使用。

Objective： To evaluate the clinical effect and significance of Zuoguiwan and Xiayuxue decoction in the treatment of primary osteoporosis （Kidney deficiency and blood stasis type）. Methods： Patients with primary osteoporosis diagnosed in our hospital from August 2013 to August 2015 were collected and those of kidney deficiency and blood stasis type were selected as research subjects and given Zuoguiwan and Xiayuxue decoction after informed consent of the patients. The effect was observed and compared with that of the conventional treatment of patients with primary osteoporosis （Kidney deficiency and blood stasis type）. Results： The total effective rate of the treatment group was significantly better than that of the control group, the difference was of statistical significance （P 〈 0.05）. The difference of BMD value of two groups before treatment was of no statistical significance （P 〉 0.05）, BMD value of the treatment group was significantly higher than that of the control group 3 months and 6 months after treatment, the difference was of statistical significance （P 〈 0.05）. Conclusion： Zuoguiwan and Xiayuxue decoction had significant effect in the treatment of primary osteoporosis （Kidney deficiency and blood stasis type）, it could increase the bone density and was worthy of clinical promotion and application.